Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

This study is for women aged 18 or older who have been diagnosed with certain types of endometrial cancer. Your doctor will need to confirm that your cancer cells have high levels of the HER2 protein. This is very important for the study.

You would be eligible if your cancer is newly diagnosed and falls into stage IIC or III, which means it has spread a little locally or to nearby areas, but not widely to other parts of the body. You must have had surgery for your cancer, but no other cancer treatment yet, like chemotherapy or radiotherapy, for this particular cancer.

However, you wouldn't be able to join if your cancer has already come back, or if it's spread widely to distant parts of your body (Stage IV). You also can't take part if you have certain other conditions, like a recent heart attack or specific heart rhythm problems, or if you still have measurable cancer remaining after your surgery.

If you decide to take part in this study, you would be randomly assigned to one of two groups, like flipping a coin. One group will receive the new medicine, trastuzumab deruxtecan, and the other will receive standard chemotherapy. Both groups might also have radiotherapy, depending on what your doctors recommend.

The study would involve regular visits to the hospital for your treatments, check-ups, and tests like blood samples and scans to see how you're responding and to check for any side effects. This will continue for a period after your treatment finishes to monitor your health. The duration of your treatment and follow-up will be discussed in detail by the study team, but generally, these types of studies involve consistent monitoring over several months or even a few years.